Harmony Biosciences Holdings (HRMY) Equity Average (2019 - 2026)

Harmony Biosciences Holdings' Equity Average history runs 8 years deep, the most recent figure standing at $890.3 million for Q1 2026.

• In Q1 2026, Equity Average rose 29.06% year-over-year to $890.3 million; the TTM figure through Mar 2026 stood at $890.3 million (up 29.06% YoY), while the FY2025 annual figure was $764.7 million, up 35.81% from the prior year.
• Equity Average came in at $890.3 million for Q1 2026 at Harmony Biosciences Holdings, up from $852.7 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $890.3 million in Q1 2026 to a low of $200.5 million in Q1 2022.
• A 5-year average of $537.7 million and a median of $491.2 million in 2024 frame the typical range for Equity Average.
• Across the five-year window, Equity Average surged 120.58% in 2022 and climbed 13.55% in 2024, its largest moves.
• Harmony Biosciences Holdings' Equity Average stood at $373.4 million in 2022, then grew by 27.0% to $474.2 million in 2023, then surged by 32.44% to $628.0 million in 2024, then soared by 35.78% to $852.7 million in 2025, then climbed by 4.41% to $890.3 million in 2026.
• According to Business Quant data, Equity Average over the past three periods registered $890.3 million, $852.7 million, and $804.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison